Alison Vogel

The impact of pacifier use on breastfeeding: A prospective cohort study

Objectives: To determine the predictors of pacifier use during the first year of life and to assess the influence of pacifier use on the duration of breastfeeding.

Cost-effectiveness of palivizumab in New Zealand

Objective:  To establish the preterm infant hospitalization risks from respiratory syncytial virus (RSV) in New Zealand and the net cost per hospitalization averted by palivizumab.

Variations in bronchiolitis management between five New Zealand hospitals: Can we do better?

Objectives:  To determine the current management of bronchiolitis by five major New Zealand hospitals and to identify areas for improvement.

Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants.

Abstract:  Palivizumab prophylaxis significantly reduces hospitalization for respiratory syncytial virus (RSV) disease in preterm infants. However, palivizumab is very expensive. Data from a New Zealand cost‐effectiveness analysis were considered by representatives of the Infectious Diseases and Immunisation, Fetus and Newborn, and Respiratory Committees of the Paediatric Society of New Zealand. Prophylaxis in all high‐risk groups was associated with net cost. The consensus panel recommends that the priority for palivizumab be given to babies discharged on home oxygen with chronic lung disease, followed by babies born at 28 weeks or less gestation.

Prevalence and impact of chronic childhood conditions in Auckland, New Zealand

Objective: To establish the prevalence of specific chronic conditions of childhood in the Auckland area and to quantify resource use by these children.

Post-streptococcal glomerulonephritis: Some reduction in a disease of disparities: Post streptococcal glomerulonephritis

A retrospective Auckland‐wide (total population approximately 1.4 million) study of hospital admissions from 2007 to 2015 was conducted to assess trends in admissions for acute post‐streptococcal glomerulonephritis (APSGN) in children aged 0–14 years.